HC Wainwright Cuts Acrivon Therapeutics (NASDAQ:ACRV) Price Target to $19.00

Acrivon Therapeutics (NASDAQ:ACRV) had its target price reduced by HC Wainwright from $22.00 to $19.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q1 2025 earnings at ($0.63) EPS, Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.77) EPS, FY2027 earnings at ($2.31) EPS, FY2028 earnings at ($1.96) EPS and FY2029 earnings at ($1.25) EPS.

A number of other brokerages have also weighed in on ACRV. KeyCorp started coverage on shares of Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating for the company. Cantor Fitzgerald started coverage on Acrivon Therapeutics in a research report on Friday, January 31st. They set an “overweight” rating for the company. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $23.17.

Acrivon Therapeutics Price Performance

NASDAQ ACRV opened at $2.24 on Wednesday. Acrivon Therapeutics has a one year low of $2.14 and a one year high of $11.90. The firm has a market cap of $69.74 million, a P/E ratio of -0.83 and a beta of 0.85. The stock’s 50-day moving average is $5.35 and its 200-day moving average is $6.53.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its earnings results on Thursday, March 27th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.06. Equities analysts anticipate that Acrivon Therapeutics will post -2.49 EPS for the current year.

Institutional Trading of Acrivon Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ACRV. State Street Corp grew its stake in Acrivon Therapeutics by 26.4% in the third quarter. State Street Corp now owns 225,896 shares of the company’s stock valued at $1,581,000 after purchasing an additional 47,233 shares in the last quarter. Barclays PLC raised its stake in shares of Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock worth $233,000 after purchasing an additional 11,273 shares in the last quarter. Exome Asset Management LLC acquired a new stake in shares of Acrivon Therapeutics in the 3rd quarter valued at approximately $817,000. JPMorgan Chase & Co. grew its stake in shares of Acrivon Therapeutics by 548.3% in the third quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after buying an additional 28,748 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Acrivon Therapeutics during the fourth quarter worth $40,000. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.